These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
305 related articles for article (PubMed ID: 28557813)
1. Diabetic Ketoacidosis as an Immune-related Adverse Event from Pembrolizumab in Non-Small Cell Lung Cancer. Leonardi GC; Oxnard GR; Haas A; Lang JP; Williams JS; Awad MM J Immunother; 2017; 40(6):249-251. PubMed ID: 28557813 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer Needing Treatment Interruption Because of Adverse Events: A Retrospective Multicenter Analysis. Ksienski D; Wai ES; Croteau N; Fiorino L; Brooks E; Poonja Z; Fenton D; Geller G; Glick D; Lesperance M Clin Lung Cancer; 2019 Jan; 20(1):e97-e106. PubMed ID: 30337270 [TBL] [Abstract][Full Text] [Related]
3. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer. Godwin JL; Jaggi S; Sirisena I; Sharda P; Rao AD; Mehra R; Veloski C J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940 [TBL] [Abstract][Full Text] [Related]
4. Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non-Small-Cell Lung Cancer Who Received Programmed Death 1 Inhibitors. Fukihara J; Sakamoto K; Koyama J; Ito T; Iwano S; Morise M; Ogawa M; Kondoh Y; Kimura T; Hashimoto N; Hasegawa Y Clin Lung Cancer; 2019 Nov; 20(6):442-450.e4. PubMed ID: 31446020 [TBL] [Abstract][Full Text] [Related]
5. Immune-mediated thrombocytopenia and hypothyroidism in a lung cancer patient treated with nivolumab. Jotatsu T; Oda K; Yamaguchi Y; Noguchi S; Kawanami T; Kido T; Satoh M; Yatera K Immunotherapy; 2018 Feb; 10(2):85-91. PubMed ID: 29260625 [TBL] [Abstract][Full Text] [Related]
6. Diabetic ketoacidosis following immunotherapy for lung cancer. Skorpen PK; Margull J Tidsskr Nor Laegeforen; 2019 Feb; 139(4):. PubMed ID: 30808100 [No Abstract] [Full Text] [Related]
7. Vitiligo in a patient with lung adenocarcinoma treated with nivolumab: A case report. Uenami T; Hosono Y; Ishijima M; Kanazu M; Akazawa Y; Yano Y; Mori M; Yamaguchi T; Yokota S Lung Cancer; 2017 Jul; 109():42-44. PubMed ID: 28577948 [TBL] [Abstract][Full Text] [Related]
9. Immunosuppression for Immune Checkpoint-related Toxicity Can Cause Pneumocystis Jirovecii Pneumonia (PJP) in Non-small-cell Lung Cancer (NSCLC): A Report of 2 Cases. Schwarz M; Kocher F; Niedersuess-Beke D; Rudzki J; Hochmair M; Widmann G; Hilbe W; Pircher A Clin Lung Cancer; 2019 May; 20(3):e247-e250. PubMed ID: 30635258 [No Abstract] [Full Text] [Related]
10. Excellent treatment response with pembrolizumab in a lung cancer patient who developed immune-mediated acute motor/sensory axonal polyneuropathy. Yen CC; Su HC; Chu CY; Lai SJ; Yan JJ; Su WP; Su WC Lung Cancer; 2018 Jun; 120():149-151. PubMed ID: 29681404 [No Abstract] [Full Text] [Related]
11. Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer. O'Kane GM; Labbé C; Doherty MK; Young K; Albaba H; Leighl NB Oncologist; 2017 Jan; 22(1):70-80. PubMed ID: 27534573 [TBL] [Abstract][Full Text] [Related]
12. Surface marker profiles on lung lymphocytes may predict the mechanism of immune-mediated pneumonitis triggered by tumor-infiltrating lymphocytes in lung cancer patients treated with pembrolizumab. Oda K; Kato K; Nakamura M; Jotatsu T; Noguchi S; Kawanami T; Kido T; Yatera K Lung Cancer; 2018 Apr; 118():171-172. PubMed ID: 29496324 [No Abstract] [Full Text] [Related]
13. Case report: pembrolizumab-induced Type 1 diabetes in a patient with metastatic cholangiocarcinoma. Smith-Cohn MA; Gill D; Voorhies BN; Agarwal N; Garrido-Laguna I Immunotherapy; 2017 Sep; 9(10):797-804. PubMed ID: 28877632 [TBL] [Abstract][Full Text] [Related]
14. FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1. Sul J; Blumenthal GM; Jiang X; He K; Keegan P; Pazdur R Oncologist; 2016 May; 21(5):643-50. PubMed ID: 27026676 [TBL] [Abstract][Full Text] [Related]
15. Patterns of immunotherapy use and management of toxicities in regional and tertiary settings. Hamilton B; Xu K; Honeyball F; Balakrishnar B; Zielinski R Intern Med J; 2019 Aug; 49(8):1010-1015. PubMed ID: 30693623 [TBL] [Abstract][Full Text] [Related]
16. Fulminant diabetes due to immune checkpoint inhibitors in the emergency department. Peyrony O; Ellouze S; Fontaine JP; Mohamadou I; Zafrani L Am J Emerg Med; 2020 Feb; 38(2):408.e3-408.e4. PubMed ID: 31759780 [TBL] [Abstract][Full Text] [Related]
17. Hypereosinophilia in a patient with metastatic non-small-cell lung cancer treated with antiprogrammed cell death 1 (anti-PD-1) therapy. Lou Y; Marin-Acevedo JA; Vishnu P; Manochakian R; Dholaria B; Soyano A; Luo Y; Zhang Y; Knutson KL Immunotherapy; 2019 May; 11(7):577-584. PubMed ID: 30943864 [TBL] [Abstract][Full Text] [Related]
18. Diffuse edema suggestive of cytokine release syndrome in a metastatic lung carcinoma patient treated with pembrolizumab. Rassy EE; Assi T; Rizkallah J; Kattan J Immunotherapy; 2017 Mar; 9(4):309-311. PubMed ID: 28303768 [TBL] [Abstract][Full Text] [Related]
19. Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition. Naqash AR; Appah E; Yang LV; Muzaffar M; Marie MA; Mccallen JD; Macherla S; Liles D; Walker PR J Immunother Cancer; 2019 Jul; 7(1):169. PubMed ID: 31277704 [TBL] [Abstract][Full Text] [Related]
20. Development of Thyroid Carcinoma During Treatment With Pembrolizumab in a Lung Cancer Patient. Gorospe L; García-Gómez-Muriel I; Pian-Arias HG; Gómez-Ramírez J; Rioja-Martín ME; Olmedo-García ME; Garrido-López P; Muñoz-Molina GM; Mezquita L Ann Thorac Surg; 2020 Jun; 109(6):e397-e399. PubMed ID: 31846639 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]